ZimVie (ZIMV) stock underwent a massive rally on Monday after the dental implants company announced an acquisition agreement with healthcare investment firm ARCHIMED. Under the terms of this deal, ARCHIMED will acquire all outstanding shares of ZIMV stock for $19 each in cash. This represents a 99% premium to the stock’s 90-day volume-weighted average price of $9.57 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
ZimVie’s Board of Directors has given its unanimous support to the deal with ARCHIMED. If all goes well, the deal will close by the end of 2025. When that happens, ZimVie will become a privately held company and ZIMV stock will no longer trade publicly.
Vafa Jamali, Chairman and CEO of ZimVie, said, “Partnering with ARCHIMED will create value for our shareholders while providing the strategic and financial backing to expand our innovative dental technology to more patients globally.”
ZIMV Stock Movement Today
News of the deal with ARCHIMED had ZIMV stock up 122.27% during pre-market trading on Monday, compared to a 2.54% drop on Friday. Even so, the stock has fallen 39.5% year-to-date and was down 61.18% over the past 12 months. Roughly 600,000 shares of ZIMV stock have traded today, versus a three-month daily average of about 133,500 units.
Is ZimVie Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for ZIMV stock is Moderate Sell, based on two Hold and one Sell rating over the past three months. With that comes an average ZIMV stock price target of $9.50, representing a potential 12.56% upside for the shares.
